Name:

Enrolment No:



UNIVERSITY OF PETROLEUM AND ENERGY STUDIES

End Semester Examination, December 2022

Course: MSc. Clinical Research Semester: 3rd

Program: Regulatory Aspects of Clinical Research and IPR Duration : 3 Hours

Course Code: HSCR8005 Max. Marks: 100

Instructions: All questions are compulsory

S. No.	Section A	Marks	COs
	Short answer questions/ MCQ/T&F		
	(20Qx1.5M= 30 Marks)		
Q1	Under which type of agreement royalties paid on the basis of sale?	1.5	CO4
	a. Mining		
	b. Patent		
	c. Copyright		
	d. licensing		
Q2	Which of the following is not the infringement of copyright?	1.5	CO4
	a. Copy the software to another computer by educational		
	institution		
	b. Copy the software to another computer by company		
	c. Copy the software to another computer		
	d. To make backup copies		
Q3	Patent can be granted for?	1.5	CO4
	a. Process		
	b. Ideas		
	c. Product		
	d. Both product and process		
Q4	What is meant by a blind subject?		
	a. The subjects do not know which study treatment they		
	receive		
	b. Patients injected with placebo and active doses	1.5	CO2
	c. Fake treatment		
	d. Signed document of the recruited patient for the		
	clinical trial procedures		

Q5	Which one of the following will perfectly fit on the marked place?		
	Approval process Data entered and reviewed	1.5	CO1
	a. Investigator selection b. Patient recruitment		
	c. Statistical Analysis		
0(d) Data filed and registration		
Q6	What is informed consent in a clinical trial?		
	a. The subjects do not know which study treatment they		
	receive	1.5	CO1
	b. Patients injected with placebo and active dosesc. Fake treatment	1.0	
	d. Signed document of the recruited patient for the clinical trial procedures		
Q7	Which one of the following will perfectly fit on the marked place?	1.5	
	Approved protocol Approval process		CO2
	a) Investigator selection		
	b) Patient recruitment		
	c) Statistical Analysis		
	d) Data filed and registration		
Q8	Who is responsible for WHO international drug monitoring	1.5	CO1
	Program?		
	a. Uppsala monitoring centreb. WHO drug dictionary		
	c. PVPI		
	d. Contract research Organization		
Q9	How many people will be selected for phase II trial?	1.5	CO1
	a. The whole market will be under surveillance		
	b. 300-3000 people		
	c. 20-300 people		
	d. 0-50 people		
Q10	The most adopted method for reporting of ADR is -	4 =	CO2
	a. Expedited reporting.	1.5	
	b. Longitudinal electronic patient records		

	c. Spontaneous reporting.		
	d. Suspected reporting		
Q11	Patent application can be filed in India by	1.5	CO2
	a. True and First Inventor		
	b. Assignee of the inventor		
	c. Legal representative of the inventor		
	d. All the above		
Q12	Which of the following is NOT included in the ICH quality	1.5	CO3
	guidelines?		
	a. Stability studies		
	b. Reproductive toxicity studies		
	c. Impurity testing		
Q13	d. Good manufacturing practice (GMP) Which of the following sources does NOT provide Individual	1.5	CO4
41 2	Case Safety Reports (ICSRs)?	1.0	
	a. Pharmaceutical companies		
	b. Clinical Research Organizations		
	c. Individual patients		
	d. Regulatory agencies		
Q14	Which of the following patients are at the highest risk of		CO1
χ	suffering from an adverse drug reaction?		001
	a. An 8 month year old infant receiving a prescription		
	for an antibiotic.		
	b. A 22 year old patient with asthma receiving		
	prescriptions for inhalers to relieve and prevent their	1.5	
	asthma.	1,0	
	c. A 48 year old patient who has hypertension and		
	receives a prescription for an ACE Inhibitor.		
	d. A 68 year old patient who has oedema receiving a		
	prescription for a diuretics		
Q15	Which of the following is NOT one of the principles of Good	1.5	CO2
~- ~	Clinical Practice (GCP)?		
	a. The well-being of subjects is of highest priority.		
	b. Trials should have a clear, defined protocol.		
	c. Informed consent of subjects must be obtained.		
	d. The protocol is approved by the trial organization.		
Q16	What is meant by "compliance" in a randomized clinical	1.5	CO3
-	trial?		
	a. Flexibility in assignment to treatment groups.		
	b. The degree to which study subjects adhere to an		
	assigned treatment protocol.		

	c. An inter-institutional agreement for a multi-center		
	study.		
	d. Benefits for people who enroll in the study.		
Q17	How many members should an Ethics Committee have?	1.5	CO4
	a. At least 3		
	b. At least 5		
	c. At least 7		
	d. There is no specification		
Q18	I am the lowest concentration of drug in the systemic		CO1
	circulation at which it can produce a therapeutic effect.		
	a. Therapeutic dose	1.5	
	b. Therapeutic Threshold	1.5	
	c. Minimum Effective Concentration		
	d. Tolerance		
Q19	I am an annual report containing all safety information for a	1.5	CO1
	product which is in development.		
	a. IND		
	b. NDA		
	c. IMPD		
	d. DSUR		
Q20	What is the following the definition of?	1.5	CO1
	"The specific project goals, deliverables, features, functions,		
	tasks, deadlines, and ultimately costs of a project"		
	a. Project Plan		
	b. Project Scope		
	c. Project Definition		
	d. Project Objective		
	Coation D		
	Section B (4Qx5M=20 Marks)		
	(4Qx5IVI=20 IVIAI KS)		
Q 1	Describe four basic principles of Belmont Report.	5	CO1
Q2	Discuss the steps in INDA filing	5	CO4
Q3	Write a brief note on regulatory aspects of clinical trials	5	CO1
Q4	Elaborate the components of Orphan Drugs Application	5	CO3
	Section C		- 1
	(2Qx15M=30 Marks)		
Q 1	Write a detailed note Council for International Organizations	15	CO2
	of Medical Sciences (CIOMS)		

Q2	Elaborate the role of IPR and its types in safeguarding	15	CO4	
	inventor/creator			
	Section D			
(2Qx10M=20 Marks)				
Q 1	Write a note on composition and responsibilities of IRB	10	CO2	
Q2	Briefly explain the principles of medical ethics relevant to	10	CO1	
	the protection of prisoners against torture.			